Therapeutic potential of AAV-mediated MMP-3 secretion from corneal endothelium in treating glaucoma

Journal article

Publication Details

Author(s): O'Callaghan J, Crosbie DE, Cassidy PS, Sherwood JM, Flügel-Koch C, Lütjen-Drecoll E, Humphries MM, Reina-Torres E, Wallace D, Kiang AS, Campbell M, Stamer WD, Overby DR, O'Brien C, Tam LCS, Humphries P
Journal: Human Molecular Genetics
Publication year: 2017
Volume: 26
Journal issue: 7
Pages range: 1230-1246
ISSN: 0964-6906


Intraocular pressure (IOP) is maintained as a result of the balance between production of aqueous humour (AH) by the ciliary processes and hydrodynamic resistance to its outflow through the conventional outflow pathway comprising the trabecular meshwork (TM) and Schlemm's canal (SC). Elevated IOP, which can be caused by increased resistance to AH outflow, is a major risk factor for open-angle glaucoma. Matrix metalloproteinases (MMPs) contribute to conventional aqueous outflow homeostasis in their capacity to remodel extracellular matrices, which has a direct impact on aqueous outflow resistance and IOP. We observed decreased MMP-3 activity in human glaucomatous AH compared to age-matched normotensive control AH. Treatment with glaucomatous AH resulted in significantly increased transendothelial resistance of SC endothelial and TM cell monolayers and reduced monolayer permeability when compared to control AH, or supplemented treatment with exogenous MMP-3.Intracameral inoculation of AAV-2/9 containing a CMV-driven MMP-3 gene (AAV-MMP-3) into wild type mice resulted in efficient transduction of corneal endothelium and an increase in aqueous concentration and activity of MMP-3. Most importantly, AAV-mediated expression of MMP-3 increased outflow facility and decreased IOP, and controlled expression using an inducible promoter activated by topical administration of doxycycline achieved the same effect. Ultrastructural analysis of MMP-3 treated matrices by transmission electron microscopy revealed remodelling and degradation of core extracellular matrix components. These results indicate that periodic induction, via use of an eye drop, of AAV-mediated secretion of MMP-3 into AH could have therapeutic potential for those cases of glaucoma that are sub-optimally responsive to conventional pressure-reducing medications.

FAU Authors / FAU Editors

Flügel-Koch, Cassandra Prof. Dr.
Medizinische Fakultät
Lütjen-Drecoll, Elke Prof. Dr.
Lehrstuhl für Anatomie II

External institutions with authors

Duke University
Imperial College London / The Imperial College of Science, Technology and Medicine
Mater Misericordiae University Hospital (MMUH) / Ospidéal an Mater Misercordiae
Trinity College Dublin
University College Dublin (UCD)

How to cite

O'Callaghan, J., Crosbie, D.E., Cassidy, P.S., Sherwood, J.M., Flügel-Koch, C., Lütjen-Drecoll, E.,... Humphries, P. (2017). Therapeutic potential of AAV-mediated MMP-3 secretion from corneal endothelium in treating glaucoma. Human Molecular Genetics, 26(7), 1230-1246.

O'Callaghan, Jeffrey, et al. "Therapeutic potential of AAV-mediated MMP-3 secretion from corneal endothelium in treating glaucoma." Human Molecular Genetics 26.7 (2017): 1230-1246.


Last updated on 2019-31-01 at 22:10